Dec
2026
Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
Visit us
stand B1.G26
Zone

Sinovac Holding Group Co., Ltd.

Exhibitor at CPHI Middle East 2026
About Us

Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the research, development, production, and commercialization of vaccines that protect against human infectious diseases.
SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    China
  • On CPHI since:
    2018
  • Certificates:
    2
  • Employees:
    1000 - 4999
Company types
Biopharmaceutical company
Primary activities
Biopharmaceutical
Clinical Research
View company profile
Contact info
Show contact info Hide contact info
Event information
CPHI Middle East 2026
  • 14 Dec 2026 - 16 Dec 2026
  • Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia
  • Visit us at stand B1.G26

Products Featured at CPHI Middle East 2026

  • Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

    Product Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains

    Launched in 2021.

    Prequalified by the World Health Organization.

    Manufacturing process is result of technology transfer from the WHO and Netherlands-based lntravacc.

    Good safety with zero preservatives and antibiotics.

    Read more on: http://ww...
  • Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

    Product Hepatitis A Vaccine (Human Diploid Cell), Inactivated - Healive®

    • Hepatitis A Vaccine (Human Diploid Cell), Inactivated – Healive® Launched in 2002

    Hepatitis A & Hepatitis B Combined Vaccine – Bilive®
    Launched in 2005

    Healive® is:
    Prequalified by the World Health Organization.
    Provides susta...
  • Influenza Vaccine (Split Virion), lnactivated – Anflu®

    Product Influenza Vaccine (Split Virion), lnactivated – Anflu®

    Influenza Vaccine (Split Virion), lnactivated – Anflu®
    Pandemic Influenza Vaccine, lnactivated, Adjuvanted – Panflu®
    H1N1 Influenza A Vaccine (Split Virion), lnactivated – Panflu.1®
    Influenza Vaccine (Split Virion), lnactivated, Quadrivalent – TetrAnflu®

    Anflu®, preservative-free ...
  • SYN023 (Zamerovimab and Mazorelvimab Injection)

    Product SYN023 (Zamerovimab and Mazorelvimab Injection)

    Zamerovimab and Mazorelvimab Injection (SYN023) is the World’s First Humanized mAb Cocktail against Rabies. It has approved in China since 2024. 

Sinovac Biotech Ltd. Resources (1)

  • SINOVAC Vaccines leaflets

    Brochure SINOVAC Vaccines leaflets

    Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases.

    SINOVAC's product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected Hand-Foot-Mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, and mumps.